Katherine A. Eade - 09 Jun 2026 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Reporting relationship: Director
Issuer ticker: HBIO
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 11:52:25 UTC
Prior SEC filing: 18 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Katherine A. Eade

Key filing fact

Katherine A. Eade filed Form 4 for HARVARD BIOSCIENCE INC (HBIO) on 12 Jun 2026.

Key facts

This page summarizes Katherine A. Eade's Form 4 filing for HARVARD BIOSCIENCE INC (HBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 11:52.

Change

Previous filing in this sequence was filed on 18 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721318 Primary reporting owner

Eade Katherine A.

Relationship: Director
Address: C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON
Signature: /s/ Katherine A. Eade
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HBIO transaction

Common Stock

Award

Transaction value
Shares: +16,556
Change %: +39%
Price: $0.000000^*
Shares after: 58,669
Date: 09 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Footnote F2

Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.

Footnote F3

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.